Prime Medicine, Inc. (PRME) Stock Forecast
PRME analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.50 / 5 from 14 analysts
- Price target
- $7.11 average of analyst targets
- Upside to target
- +105.0% from the latest close
- Next earnings
- November 6, 2026 EPS estimate $-0.23
- 52-week range
- $2.70 – $6.18
PRME analyst ratings
14 analystsNumber of analysts at each rating.
PRME price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
PRME earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.23 | −$0.28 | −$0.19 | −$0.32 | +27.0% | 13 |
| Current fiscal year (2026) | −$0.94 | −$1.11 | −$0.81 | −$1.35 | +30.0% | 14 |
| Next fiscal year (2027) | −$0.89 | −$1.22 | −$0.67 | −$0.94 | +6.0% | 12 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
PRME revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.1M | $0 | $3.0M | −10.5% | 11 |
| Current fiscal year (2026) | $8.8M | $2.0M | $53.0M | +90.6% | 13 |
| Next fiscal year (2027) | $10.6M | $0 | $62.0M | +19.5% | 13 |
PRME EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
PRME revenue: reported and forecast
PRME EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.23 | −$0.23 | −$0.23 | −$0.23 | −$0.23 | +2.8% | 1 up · 1 down |
| Current fiscal year (2026) | −$0.99 | −$0.92 | −$0.93 | −$0.94 | −$0.94 | −4.1% | 7 up · 3 down |
| Next fiscal year (2027) | −$0.84 | −$0.89 | −$0.88 | −$0.89 | −$0.89 | +5.5% | 3 up · 5 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
PRME earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; PRME beat in 4 of 12.
What analysts expect from PRME
14 analysts cover Prime Medicine; their consensus rating is strong buy (4.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $7.11, 105.0% above the latest close of $3.47. Analysts expect earnings of −$0.94 per share for 2026, +30.0% from a year earlier. For 2027 the average estimate is −$0.89 per share on revenue of $10.6 million. Prime Medicine beat the EPS estimate in 4 of the last 12 quarters.
Related: PRME income statement, PRME key metrics, PRME chart. See the PRME stock overview for the latest quote and news.
PRME forecast FAQ
What is Prime Medicine's price target?
The average analyst price target for Prime Medicine is $7.11, 105.0% above the latest close of $3.47.
Is Prime Medicine a buy, hold or sell?
Of 14 analysts covering Prime Medicine, 10 rate it a strong buy, 1 a buy, 3 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Prime Medicine's EPS forecast?
Analysts forecast −$0.94 per share for 2026 (range −$1.11 to −$0.81); for 2027 the estimate is −$0.89.
What is Prime Medicine's revenue forecast?
The average revenue estimate for 2026 is $8.8 million, growth of 90.6%; for 2027 it is $10.6 million.
When does Prime Medicine report earnings?
Prime Medicine is expected to report results for the quarter ending September 30, 2026 on November 6, 2026 before the market opens; the EPS estimate is $-0.23.
Does Prime Medicine usually beat earnings estimates?
Prime Medicine reported EPS at or above the analyst estimate in 4 of the last 12 quarters.